Clinical Guidelines > Current Guidelines >

BHIVA and BIA guidelines for the treatment of Opportunistic Infection in HIV-seropositive Individuals 2011

Introduction

Advances in the treatment of HIV infection with antiretroviral therapy have led to dramatic reductions in opportunistic infections and death. However, late presentation of HIV remains a problem and is a significant contributory cause to death in HIV-seropositive persons in the UK [1]. Furthermore, a recent UK Health Protection Agency (HPA) analysis showed that of 46 700 patients with diagnosed HIV, 19% had CD4 counts o200 cells/mL [2] and therefore remain at significant risk of opportunistic infection.

These guidelines have been drawn up to help physicians investigate and manage HIV-seropositive patients suspected of, or having an opportunistic infection (OI). They are primarily intended to guide practice in the UK and related health systems.

Treatment of Opportunistic Infection in HIV-seropositive Individuals (2011)


Downloads

British HIV Association and British Infection Association Guidelines for the Treatment of Opportunistic Infection in HIV-seropositive Individuals 2011


Writing Group

M Nelson, DH Dockrell and S Edwards on behalf of the BHIVA Guidelines Subcommittee
(See Appendix 2 for list of members of the BHIVA Guidelines Writing Group on Opportunistic Infection)


Reference

HIV Medicine (2011), 12 (Suppl. 2), 1-140.